Majority of Individuals with Atopic Dermatitis Improved

Arcutis today announced new individual patient response data in Atopic Dermatitis with roflumilast cream according to new data from Phase 3 program...

Related Keywords

United States ,Hawaii ,Honolulu ,Derek Cole ,Amanda Sheldon ,Drug Administration ,Head Of Corporate Communications ,Arcutis Biotherapeutics Inc ,Exchange Commission ,Nasdaq ,Facebook ,Investor Relations Advisory Solutions ,Eczema Area ,Severity Index ,Clinical Dermatology Conference ,Patients With Atopic Dermatitis ,Individual Patient ,Prescription Drug User Fee Act ,Private Securities Litigation Reform Act ,Relations Advisory ,Nasdaq Arqt ,Arcutis Biotherapeutics ,Nc ,Winter Clinical ,Atopic Dermatitis ,Roflumilast Cream ,